Allarity Therapeutics is focused on the clinical development of two priority programs: Stenoparib and Ixempra®. Each Allarity pipeline program is being co-developed with a drug specific DRP® companion diagnostic to select and treat patients most likely to benefit from treatment.
In addition, Allarity is supporting the development of several other clinical assets through business development activities.